Last reviewed · How we verify
NCT04824053
Effects of UNICLA-A2 Dairy Products on Patients At High-risk of Colorectal Cancer Development
NA trial testing Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium in Colorectal Polyp in 34 participants. Currently enrolling.
30 November 2025
Quick facts
| Lead sponsor | Instituto de Investigación Sanitaria Aragón |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 34 |
| Start date | 28 February 2022 |
| Primary completion | 30 November 2025 |
| Estimated completion | 15 December 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
- Conventional milk
- Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
- Conventional yogurt
- Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium
- Conventional fresh cheese
Conditions studied
- Colorectal Polyp — all drugs for Colorectal Polyp →
Sponsor
Instituto de Investigación Sanitaria Aragón — full company profile →
Who can join
Adults 18 to 80, any sex, with Colorectal Polyp. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce inflammatory processes, normalize the immune system, protect against oxidative damage and equilibrate the gut microbiota in high-risk colorectal cancer patients who have undergone polypectomy
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04824053
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Polyp
Currently open trials in the same condition.
- NCT06791408 — Clinical Study on the Accuracy of Real-time AI-assisted Endocytoscopy in the Diagnosis of Colorectal Diminutive Polyps · recruiting
- NCT06715384 — Evaluation of a CAM System for Colorectal Polyp Size Measurement · NA · recruiting
- NCT06193356 — Detection of Endoscopic Resection Scars and Delineation of Recurrence is Trainable · NA · recruiting
- NCT06502704 — Bile Acids and Microbiome in Early Colorectal Carcinogenesis · recruiting
- NCT06447012 — Artificial Intelligence Development for Colorectal Polyp Diagnosis · recruiting
Other Instituto de Investigación Sanitaria Aragón trials
Trials by the same sponsor.
- NCT07070531 — Unified Protocol in Penitentiary Facilities · NA · not yet recruiting
- NCT07185412 — Spanish Registry of Redo Procedures Following Pulmonary Vein Ablation by Pulsed Field Ablation Technology: RESET-PFA · not yet recruiting
- NCT07321444 — Telerehabilitation in Shoulder Pathology · NA · completed
- NCT06547450 — Unified Protocol for Treatment of Emotional Disorders in Brief Groups in Primary Care Services in Spain · NA · not yet recruiting
- NCT06928480 — Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Peop · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04824053 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto de Investigación Sanitaria Aragón
- Last refreshed: 27 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04824053.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing